IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026
IceCure Medical (NASDAQ: ICCM) will release its financial and operating results before the market opens on November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IceCure Medical (NASDAQ: ICCM) will release its financial and operating results before the market opens on November 18, 2026.
The results will cover the nine months ended September 30, 2026. The company will discuss the results and other corporate developments on a conference call at 10:00 a.m. EST that same day. A live webcast and a recording will be available.
Key Figures
- Results release date
- November 18, 2026
- 3Q 2026 financial and operating results; before the Nasdaq market opens
Key Terms
cryoablation medical
adjuvant endocrine therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call & webcast info:
Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its expected announcement of financial and operational results as of and for the nine months ended September 30, 2026 and hosting a conference call related to such results. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Meir Peleg, CFO
investors@icecure-medical.com
+1-888-902-5716
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2026-financial-and-operating-results-on-november-18-2026-302936442.html
SOURCE IceCure Medical